healio.com /2 weeks ago

Zanidatamab regimens improve survival for gastroesophageal cancer

First-line zanidatamab-hrii plus chemotherapy, without or with tislelizumab-jsgr, extended survival 24% and 35% vs. trastuzumab plus chemotherapy for those with locally advanced or...

Read source
bioengineer.org /1 week ago

Second-Line Trastuzumab Deruxtecan Yields 23-Month Progression-Free Survival in Gastroesophageal Cancer

A 63-year-old patient with HER2-positive metastatic gastroesophageal junction adenocarcinoma achieved 23 months of progression-free survival on second-line trastuzumab deruxtecan f...

Read source
aacr.org /1 month ago

HER2-targeted Therapy for Salivary Gland Cancer

Salivary gland cancer is rare, and there are no standard treatments for advanced-stage disease. Recent research supports the use of HER2-targeted therapy for patients with metastat...

Read source
pharmexec.com /1 month ago

<![CDATA[FDA Approves Tukysa Plus Trastuzumab and Pertuzumab as First-Line Maintenance Treatment for HER2-Positive Me...

Read source
qchron.com /3 weeks ago

Results of CARsgen's Satri-cel for Adjuvant Treatment for Gastric Cancer Presented at ESMO Congress 2026

SHANGHAI, Oct. 25, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that...

Read source
qchron.com /3 weeks ago

Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvaluma...

HONG KONG, Oct. 25, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced the presentation of results from the randomized, controlled, double-blind, multicenter, registr...

Read source
pharmexec.com /1 month ago

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Tukysa Plus Trastuzumab and Pertuzumab]]>

Read source
qchron.com /4 weeks ago

RYBREVANT FASPROâ„¢ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-lin...

Responses were deep and durable, with 65% ongoing at clinical cutoffResults support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line P...

Read source
biopharmadive.com /3 weeks ago

BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer study

The companies said the findings suggest the treatment has a “limited” impact in HER2-low breast cancer, an area where AstraZeneca and Daiichi Sankyo’s Enhertu has already set a hig...

Read source
qchron.com /2 weeks ago

Ivonescimab Receives NMPA Priority Review for First-Line Biliary Tract Cancer

HONG KONG, Nov. 4, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced that ivonescimab in combination with chemotherapy for the first-line treatment of locally advanc...

Read source
ekathimerini.com /1 day ago

A new hope against pancreatic cancer

A pancreatic cancer drug is now available in Greece, offering an option for patients with advanced disease.

Read source
pharmexec.com /1 month ago

<![CDATA[FDA Approves Tecentriq for Stage III dMMR Colon Cancer]]>

Read source
qchron.com /1 month ago

Hengrui Pharma Previews ESMO Congress 2026: 64 Research Findings Highlight Continued Progress Across Innovative Pipeline...

64 research findings have been accepted, including three Proffered Paper presentations and three Rapid Oral presentations, spanning more than ten areas of oncology and supportive c...

Read source
biopharmadive.com /4 days ago

Roche breast cancer pill cleared by FDA

Wilserdly’s U.S. approval is seen by analysts as a “key first step” in an important launch for Roche, which has claimed the drug could become its top-selling product.

Read source
drugs.com /4 days ago

New Pill Combo, Wilserdly + Everolimus, Approved For Breast Cancer That Stops Responding To Hormone Therapy

TUESDAY, Nov. 17, 2026 — People with advanced breast cancer that has stopped responding to hormone therapy now have a new pill-based treatment option. The U.S. Food and Drug Admini...

Read source
drugs.com /4 days ago

New Pill Combo Approved For Breast Cancer, Wilserdly, That Stops Responding To Hormone Therapy

TUESDAY, Nov. 17, 2026 — People with advanced breast cancer that has stopped responding to hormone therapy now have a new pill-based treatment option. The U.S. Food and Drug Admini...

Read source
healio.com /1 month ago

FDA OKs Lyrfigtu for previously treated bile duct cancer

The FDA approved lirafugratinib — a kinase inhibitor — for adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma.The indication for lirafug...

Read source
qchron.com /4 weeks ago

Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-ta...

Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity observed acr...

Read source
koreatimes.co.kr /1 month ago

HLB resubmits FDA application for liver cancer treatment

Korean drugmaker HLB has resubmitted its application for U.S. approval of a combination therapy for advanced liver cancer, renewing its push to bring the target treatment to market...

Read source
qchron.com /4 weeks ago

Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ES...

Median OS was extended by 8.5 months compared with platinum-based doublet chemotherapy (25.9 vs 17.4 months), with a 31% reduction in the risk of death (HR 0.69; 95% CI 0.54–0.89;...

Read source
pharmexec.com /1 month ago

<![CDATA[FDA Grants Accelerated Approval to Jemperli for MSI-H/dMMR Locally Advanced Rectal Cancer]]>

Read source
pharmexec.com /2 weeks ago

<![CDATA[FDA Grants Accelerated Approval to Rybrevant Faspro in Head and Neck Cancer]]>

Read source
biopharmadive.com /5 days ago

CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trial

CG’s therapy cretostimogene cut the risk of recurrence by 68% when administered after surgery, far surpassing Wall Street’s expectations and lifting company shares. 

Read source
investing.com /5 days ago

Roche gets FDA approval for advanced breast cancer pill

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.